Comparison of Cerus Corporation (CERS) and Esperion Therapeutics Inc. (NASDAQ:ESPR)

We are contrasting Cerus Corporation (NASDAQ:CERS) and Esperion Therapeutics Inc. (NASDAQ:ESPR) on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus Corporation 60.91M 13.76 57.56M -0.42 0.00
Esperion Therapeutics Inc. N/A 0.00 201.81M -6.75 0.00

Table 1 demonstrates Cerus Corporation and Esperion Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Cerus Corporation -94.50% -67.9% -37.4%
Esperion Therapeutics Inc. 0.00% -91.3% -77.2%

Risk and Volatility

A beta of 1.45 shows that Cerus Corporation is 45.00% more volatile than Standard and Poor’s 500. Esperion Therapeutics Inc. on the other hand, has 2.15 beta which makes it 115.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Cerus Corporation are 3.5 and 3.2. Competitively, Esperion Therapeutics Inc. has 4 and 4 for Current and Quick Ratio. Esperion Therapeutics Inc.’s better ability to pay short and long-term obligations than Cerus Corporation.

Analyst Recommendations

Cerus Corporation and Esperion Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerus Corporation 0 0 1 3.00
Esperion Therapeutics Inc. 1 3 4 2.50

Cerus Corporation’s upside potential currently stands at 47.06% and an $9 consensus price target. Meanwhile, Esperion Therapeutics Inc.’s consensus price target is $67.75, while its potential upside is 35.85%. The information presented earlier suggests that Cerus Corporation looks more robust than Esperion Therapeutics Inc. as far as analyst belief.

Insider and Institutional Ownership

Institutional investors owned 68.4% of Cerus Corporation shares and 0% of Esperion Therapeutics Inc. shares. Cerus Corporation’s share owned by insiders are 0.5%. Competitively, insiders own roughly 2.2% of Esperion Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerus Corporation 2.49% 10.57% 24.81% -12.95% 52.55% 29.98%
Esperion Therapeutics Inc. -1.37% -0.52% -11.78% -7.08% -39.96% 0.46%

For the past year Cerus Corporation was more bullish than Esperion Therapeutics Inc.

Summary

On 9 of the 11 factors Cerus Corporation beats Esperion Therapeutics Inc.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.